NCT03182179View on ClinicalTrials.gov

Efficacy of Ondansetron in LARS Treatment

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2021

Conditions
Rectal Cancer
Interventions
DRUG

Ondansetron 4 MG

Ondansetron is taken orally BD

DRUG

Placebo

Placebo is taken orally BD

Trial Locations (2)

1011

CHUV, Lausanne

6900

Ospedale Regionale di Lugano, Civico e Italiano, Lugano

All Listed Sponsors
lead

Ente Ospedaliero Cantonale, Bellinzona

OTHER

NCT03182179 - Efficacy of Ondansetron in LARS Treatment | Biotech Hunter | Biotech Hunter